Society of Urologic Oncology Annual Meeting (SUO) | Conference

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.

The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.

Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.

Data for a key study secondary outcome measure showed that 56.1% of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

Researchers identified the prevalence of germline mutations associated with the early-onset renal cell carcinoma, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

A phase 2 study found that the investigational HIF-2α inhibitor MK-6482 has durable efficacy in patients with Von Hippel-Lindau associated clear cell renal cell carcinoma and non-renal lesions.

A clear and reliable biomarker to select patients with prostate cancer for active surveillance or focal therapy has not yet been determined but inferring a course of action from existing biomarkers may be possible.